Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster ...

Novo Nordisk (NVO) stock rises after full results from an early-stage trial of weight-loss pill amycretin. Read more here.

The first-in-human study has found that participants who received 50mg amycretin reduced their body weight by 10.4 per cent ...

Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an ...

Novo Nordisk's experimental weight-loss pill, amycretin, demonstrated safety and tolerability in early-stage trials. The pill showed significant weight reduction, with patients losing up to 13.1% of ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

A new drug called amycretin is stepping into the spotlight, boasting impressive results that have both researchers and those ...